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Abstract 
The structural properties of acetyl- (ACHE) and butyrylcholinesterase (BuChE) in meningioma and the possible relationship with brain 
and plasma were investigated. Meningioma ChEs were extracted with saline and saline-Triton X-100 buffers. The tumor ChE forms were 
identified by sedimentation analysis, and their amphiphilic/hydrophilic behaviour was assessed by Triton X-114 phase-partitioning and 
hydrophobic chromatography. Meningioma contained amphiphilic globular AChE dimers (G A) and monomers (GA), and hydrophilic 
BuChE tetramers (Gan). The conversion of G A into G ¢ AChE by reduction confirmed their structures. In contrast to the meningioma 
species, brain G ¢ AChE forms remained amphiphilic after incubation with alkaline hydroxylamine and phosphatidylinositol-specific 
phospholipase C (PIPLC). Meningioma G p and PIPLC-converted G~, and brain G p AChE showed similar rate constants for thermal 
inactivation, and this suggested that the thermal stability of AChE subunits was unaffected by the presence or not of phosphatidylinositol 
residues. AChE in meningioma nd brain did not differ in the interaction with the lectins Con A, LCA, WGA and RCA. BuChE in 
meningioma and brain bound to a similar extent o Con A, LCA and WGA-Agarose, whereas one-half of BuChE in the tumor, all in 
plasma nd little in brain was fixed by RCA. Therefore, meningioma possesses RCA ÷- and RCA--BuChE, the former predominating in 
brain and the latter in plasma. It remains to be clarified whether the tumor RCA+-BuChE is intrinsic or derived from plasma. 
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1. Introduction 
Cholinesterases are polymorphic enzymes which hydro- 
lyze the neurotransmitter acetylcholine and other esters. 
Two classes of cholinesterases (ChEs) are found in tissues: 
acetylcholinesterase (ACHE, EC 3.1.1.7) and butyryl- 
cholinesterase (BuChE, EC 3.1.1.8). Both ChEs differ in 
substrate specificity and sensitivity to inhibitors [1-3]. 
ChEs exist in an array of molecular forms which are 
Abbreviations: ACHE, acetylcholinesterase; BuChE, butyryl- 
cholinesterase; CSF, cerebrospinal fluid; DTNB, 5,5'-dithio-bis-2-nitro- 
benzoic acid; Iso-OMPA, tetraisopropyl pyrophosphoramide; BW284c51, 
1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one dibr mide; PI- 
PLC, phosphatidylinositol-specific phospholipase C; GPI, glycosylphos- 
phatidylinositol; Brij 96, polyoxyethylene-10-oleyl ther; DTT, dithio- 
threitol; NEM, N-ethylmaleimide; Con A, concanavalin A; LCA, Lens 
culinaris agglutinin; WGA, wheat germ agglutinin; RCAI20, Ricinus 
communis agglutinin; SB, saline buffer (1 M NaC1, 50 mM MgCI 2, 10 
mM Tris, pH 7.0); STB, saline-Triton X-100 buffer (0.5% w/v Triton 
X-100 in SB) 
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classified into asymmetric (A12, A 8, A4) and globular 
(G4, G2, G1) forms [1,2]. AChE is involved in the termina- 
tion of neurotransmission at cholinergic synapses but other 
non-cholinergic functions have been suggested for ChEs 
[4-8]. Genetic analyses have mapped the human AChE 
gene to the long arm of chromosome 7, 7q22 region, and 
the BuChE gene to chromosome 3, 3q26-ter region [3]. 
AChE and BuChE genes are transiently expressed in sev- 
eral embryonic ell types in a manner suggesting develop- 
mentally related functions. Moreover, ChEs genes are 
overexpressed in oogenesis, spermatogenesis, embryogene- 
sis, hemopoiesis, and tumorogenesis [1,3]. 
Tumors of the central nervous system account for ap- 
prox. 9% of all primary neoplasms in humans [9]. About 
85% of these arise in the intracranial cavity. Tumors of 
neurogenic origin constitute 40-50% of intracranial tu- 
mors and represent he largest class of brain neoplasms. 
Tumors of the covering elements, the meninges, account 
for 13-18% [ 10] and constitute the second largest group of 
brain tumors. Most meningiomas are benign [11 ], but some 
of them exhibit aggressive malignant behaviour which 
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PII S0925-4439(96)00061-0 
J. Srez-Valero, C.J. Vidal / Biochimica et Biophysica Acta 1317 (1996) 210-218 211 
frequently leads to progressive neurological dysfunction 
and even death [9]. The molecular mechanisms involved in 
promotion, progression, recurrence, and malignancy of 
brain tumors are at present unknown. Meningiomas arise 
from meningothelial cells of mesenchymal origin. The 
neoplasm is composed of cells in an undifferentiated state, 
which express cholinesterase activity [12,13]. Amplifica- 
tion of ChE genes might enhance the rate of tumor cell 
growth [3,14]. Moreover, alterations in ChE activity of 
cells may be related with neoplasm relapse and/or progress 
and could be used as a prognostic/diagnostic index. 
This paper is devoted to the analysis of the structural 
characteristics of AChE and BuChE in human menin- 
gioma. The properties of cholinesterases in other intracra- 
nial tumors are currently being investigated. 
2. Materials and methods 
2.1. Materials 
All reagents were of analytical grade. Acetylthiocholine 
and butyrylthiocholine iodide, DTNB, BW284c51, Iso- 
OMPA, antiproteinases, DTT, sodium iodoacetate, NEM, 
Brij 96, phenyl-Agarose, Sepharose 4B, immobilized 
lectins (Con A- and LCA-Sepharose, WGA- and RCA120- 
Agarose), and enzyme markers for sedimentation a alysis 
were all obtained from Sigma. Sucrose, Triton X-100 and 
Triton X-114 were from Merck. Prior to its use, Triton 
X-114 was subjected to precondensation [15]. Phos- 
phafidylinositol-specific phospholipase C (PIPLC) from 
Bacillus thuringiensis was obtained from Funakoshi Co. 
(Tokyo). 
2.2. Methods 
2.2.1. Solubilization of  cholinesterases 
Intracranial tumors free of necrosis were taken from 
patients immediately after surgical operation. Each tumor 
sample was examined by conventional histological tech- 
niques, and the rest was stored in liquid nitrogen for 
further use. Meningiomas were thawed, weighed, washed 
and homogenized (10% w/v)  in 1 M NaC1, 50 mM 
MgC12, 10 mM Tris-HC1, pH 7.0 (Tris-saline buffer, SB) 
containing several proteinase inhibitors [15]. After cen- 
trifugation at 100000 X g for 1 h at 4°C, the supernatant 
S~ was recovered. This first preparation was rich in soluble 
and loosely-bound cholinesterases. The residual pellet was 
re-extracted with STB (SB containing 1% w/v  Triton 
X-100) and antiproteinases. After centrifugation asbefore, 
the membrane-bound ChEs were separated in the super- 
natant S 2. 
Since meningioma is rich in AChE dimers and 
monomers (see below), and human brain contains a re- 
duced fraction (20%) of enzyme monomers in SB extracts 
[15], it was considered of interest o investigate a possible 
structural relationship between G 1 forms in meningioma 
and brain. For this purpose, brain AChE monomers were 
extracted with SB, concentrated by phenyl-Agarose chro- 
matography and identified by sedimentation a alysis [15]. 
Possible structural differences between G~ AChE in 
meningioma nd brain were investigated by sensitivity to 
PIPLC, thermal stability and lectin interaction. To estab- 
lish whether meningioma ChEs are released to the cere- 
brospinal fluid (CSF), 5-ml samples of lumbar fluid from 
normal individuals and from subjects with meningioma 
were taken by a conventional method, centrifuged at 1000 
× g and stored at -70°C until used. 
2.2.2. Enzymatic assays 
AChE activity was spectrophotometrically ssayed by 
the Ellman method [16]; AChE with 1 mM acetylthio- 
choline and 50/zM Iso-OMPA, and BuChE activity with 1 
mM butyrylthiocholine and 10/zM BW284c51. Iso-OMPA 
and BW284c51 are relatively specific inhibitors for BuChE 
and ACHE, respectively [1,3]. One unit of ChE activity 
represents the amount of enzyme which hydrolyzes one 
/zmol of the substrate per hour, at 37°C. AChE and BuChE 
activities in fractions recovered from sucrose gradients 
were measured by a microtiter assay [17], and they are 
expressed in arbitrary units. Protein content in membrane 
suspensions and in soluble fractions was determined as 
reported before [15]. 
2.2.3. Sedimentation analysis 
Molecular forms of AChE and BuChE in the super- 
natants Sl and S 2 were separated and characterized accord- 
ing to their sedimentation coefficients [15,18]. The possi- 
ble appearance of aberrant ChE forms in CSF of patients 
with meningioma was tested by subjecting samples of CSF 
to sedimentation a alysis, the results being compared with 
those obtained from normal fluids. Samples were cen- 
trifuged on 5-20% (w/v)  linear sucrose gradients. The 
sucrose solutions were prepared in SB with Brij 96 (0.5% 
w/v)  or with Triton X-100 (0.5% w/v). Centrifugation 
was performed at 150000 X g in a SW 41Ti Beckman 
rotor for 18 h at 4°C. About 40 fractions were collected 
from the bottom of each tube and assayed for ACHE, 
BuChE and enzyme markers with known sedimentation 
coefficients: catalase (11.4S) and alkaline phosphatase 
(6.1S). 
2.2.4. Disulfide bridges reduction 
The true quaternary structure of AChE forms in menin- 
gioma was assessed by reduction of the supposed enzyme 
dimers. A mixture of S 1 + S 2 was centrifuged in Brij 
96-containing sucrose gradients. Fractions with high AChE 
activity were pooled and dialyzed to remove sucrose. 
Then, 10 mM DTT was added and the mixture incubated 
for 40 min, at 37°C. The reaction was stopped by adding 
100 mM sodium iodoacetate, the pH adjusted to 8.5 and 
the mixture incubated in the dark for 40 min at 25°C. 
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Finally, the solution was dialyzed to remove the excess of 
reagents, and the reduced and alkylated AChE forms were 
identified by sedimentation a alysis. 
2.2.5. Separation of amphiphilic and hydrophilic AChE 
and BuChE forms 
Amphiphilic and hydrophilic ChE components in a 
mixture of the supernatants S 1 and S 2 were separated by 
Triton X-114 phase-partitioning, as described before [19]. 
Amphiphilic and hydrophilic enzyme forms were concen- 
trated in the detergent-rich and aqueous phases, respec- 
tively. 
Amphiphilic ChE forms in the supernatant S 1 from 
meningioma were separated by hydrophobic hromatogra- 
phy on phenyl-Agarose [15]. The matrix-bound proteins 
were eluted with Triton X-100 (2% w/v)  in SB, and the 
resoved amphiphilic and hydrophilic ChE forms identified 
by their sedimentation coefficients. The human brain G A 
AChE forms were isolated by the same procedure [15]. 
2.2.6. Treatments with PIPLC and alkaline hydroxylamine 
We have previously reported that the amphiphilic AChE 
dimers and monomers in meningioma are partly converted 
into their hydrophilic variants by incubation with PIPLC 
[20]. The possible occurrence of a GPI residue in brain G A 
AChE species was investigated by exposing the enzyme 
released in S~ to PIPLC. Brain monomers were concen- 
trated by phenyl-Agarose chromatography and incubated 
with 1 U /ml  PIPLC from B. thuringiensis for 2 h at 36°C. 
A sample of AChE from bovine erythrocyte, which is 
known to be sensitive to PIPLC [21], was incubated in 
parallel. Conversion of amphiphilic into hydrophilic forms 
was assessed by Triton X-114 phase-partitioning and by 
sedimentation analysis. About 80% of the amphiphilic 
AChE from bovine erythrocyte was transformed into hy- 
drophilic components by exposure to PIPLC, but brain 
monomers still displayed amphiphilic properties after incu- 
bation with the phospholipase. Then, hydroxylaminolysis 
was attempted to cleave possible acyl residues linked to 
the inositol ring by an ester bond. Concentrated hydroxyl- 
amine was added to samples of brain AChE monomers to 
a final concentration of 1 M. The pH was carefully ad- 
justed to 10.2-10.5 and the mixture incubated for 20 h at 
25°C. Samples were then neutralized and the excess of 
hydroxylamine r moved by passing the samples through a 
Sephadex G-25 column, using 0.1% Triton X-100 in SB as 
equilibrium buffer. Fractions with AChE activity were 
pooled, and an aliquot was subsequently treated with PI- 
PLC as described above. Samples incubated with alkaline 
hydroxylamine, without and with a further incubation with 
the phospholipase, were subjected to Triton X-114-phase 
partitioning and to sedimentation a alysis in Triton X-100- 
and Brij 96-containing sucrose gradients. A sample of the 
PIPLC-resistant AChE from human erythrocyte, which is 
known to lose its hydrophobic anchor after incubation with 
alkaline hydroxylamine [22], was used as a control. 
2.2.7. Thermal inactivation experiments 
To gain an insight into possible differences in the 
folding of AChE subunits of the amphiphilic and PIPLC- 
converted hydrophilic monomers from meningioma, and 
the amphiphilic monomers from brain, the enzyme forms 
were subjected to thermal inactivation. Meningioma am- 
phiphilic and hydrophilic AChE monomers were obtained 
by extracting a tumor-rich in G A forms with STB or with 
STB + PIPLC and then isolated by sedimentation a alysis. 
Brain amphiphilic monomers were concentrated by 
phenyl-Agarose chromatography. The heat sensitivity of 
meningioma G A and PIPLC-converted G H forms, and 
brain G A AChE species was investigated by incubating the 
samples at 50°C in a water bath for various periods of 
time. The temperature was measured with a microprobe 
fitted inside a glass tube filled with SB and heated in 
parallel with the samples. Aliquots of 25 /~1 were with- 
drawn at different time intervals and assayed for AChE 
activity by a microtiter assay [17], at 25°C. Thermal inacti- 
vation curves were resolved with a computer-assisted non- 
linear regression algorithm. 
2.2.8. Interaction of cholinesterases with lectins 
Possible differences in the oligosaccharidic moieties of 
ChEs from meningioma, human brain and erythrocytes 
was investigated by enzyme interaction with several lectins. 
The soluble fractions S 1 and S 2, or a mixture of S~ + S 2 
from meningioma, isolated AChE monomers from brain 
and samples of Triton-solubilized AChE from human ery- 
throcyte (1 ml each) were mixed with 0.5 ml of the 
lectin-free Sepharose 4B (used as control) and with the 
immobilized lectins Con A, LCA, WGA and RCA. The 
suspensions were incubated overnight at 4°C, the beads 
with the enzyme-lectin complexes were sedimented by 
centrifugation [23] and the unbound AChE and BuChE 
activities assayed in the supernatants. 
3. Results 
3.1. Solubilization of cholinesterases from meningioma 
Cholinesterase activity was determined in twelve 
meningiomas. The AChE activity in the tissue suspensions 
prepared in STB ranged between 0.559-0.056 U/mg pro- 
tein, the BuChE activity between 0.087-0.017 U/mg,  and 
the AChE/BuChE ratios between 6.49-1.16 [20]. The 
AChE and BuChE activities in the tumor suspensions 
made in STB with antiproteinases were considered as the 
100% values. AChE and BuChE were fully released from 
meningioma by the two-step extraction procedure, about 
25% of the AChE and 75% of the BuChE activities were 
released by extracting the tissue with SB (S1), and the rest 
with STB ($2). The results indicated that most of AChE in 
meningioma was firmly associated to membranes, whereas 
BuChE was soluble or loosely bound to membranes. 
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Fig. 1. Representative s dimentation profiles of AChE and BuChE forms 
in human meningioma. A first supernatant $1was obtained from tumor 6 
(Table 1) by extracting it (10% w/v)  with a saline buffer (SB) and 
antiproteinases. The pellet was re-extracted with SB containing 1% Triton 
X-100 (STB) and antiproteinases, and the fraction S 2 recovered by 
centrifugation. ChE forms in S I (1) and S 2 (2) were separated by 
centrifugation on linear sucrose gradients (5-20% w/v)  made with Brij 
96 (0.5% w/v).  The enzyme peaks were assigned to individual molecular 
forms according to previous results [15,18]. The internal standards were 
catalase (C) and alkaline phosphatase (P). 
As regards the ChE activity in CSF of patients uffering 
from meningioma, no significant differences in the AChE 
values were found between samples from normal individu- 
als (14.5 __+ 3.1 U/ml, [24,25]) and from patients with 
meningioma (11.0 ___ 4.2 U/ml). However, BuChE tended 
to be higher in meningioma CSF (normal values: 7.3 + 2.5 
U/ml;  tumor samples: 29.9, 6.4 and 17.3 U/ml). Unfortu- 
nately, further esults on AChE and BuChE content in CSF 
of affected subjects are difficult to obtain because the 
severe clinical problems associated with CSF extraction 
from patients with brain neoplasms. However, the in- 
creased level of BuChE and protein in CSF of patients 
with meningioma probably reflects changes in the 
blood/brain barrier, with the subsequent increase of plasma 
BuChE in the fluid. Leakage of plasma BuChE into CSF 
has been previously shown by the interaction of the en- 
zyme with the Ce-D-galactose-specific le tin RCA [26]. 
Twelve tumors were extracted with SB and STB, the 
distribution of AChE and BuChE forms in S~ and S 2 being 
established by sedimentation a alysis. Two AChE forms of 
4.3S and 2.7S were identified in sucrose gradients made 
with Brij 96 (Fig. 1), although their relative proportions 
varied in the tumors investigated (Table 1). In agreement 
with previous data [15,18], the above AChE forms should 
correspond to globular dimers (G 2) and monomers (Gt). 
Both enzyme forms overlapped at 4.0-4.5S in gradients 
with Triton X-100 (profiles not shown), and their distinct 
migration in gradients with Brij 96 or with Triton X-100 
suggested that they displayed amphiphilic properties. 
Low amounts of 9.5S (G4 A) AChE forms along with 
significant proportions of 11.5S (G A) BuChE species were 
detected in the supernatant S 2 obtained from two of the 
twelve meningiomas investigated (Table 1), but because 
they were found in some pieces of the tumor but not in 
others they were considered to arise from a contamination 
of meningioma with brain tissue. 
The conversion of the 4.3S into the 2.7S AChE forms 
by reduction and alkylation (Fig. 2) demonstrated the exact 
nature of the enzyme components. Furthermore, the addi- 
tion of 5 mM NEM to the extraction buffer had no effect 
on the distribution of the two AChE forms, although about 
one-half of the AChE and BuChE activity was lost by this 
treatment. Since a mixture of antiproteneinases was always 
added to the solubilization buffers, the results demon- 
Table 1 
Molecular forms of ChEs in human meningioma 
Tumor AChE forms (%) BuChE forms (%) 
G A GI A G H G H +G H 
1 85 15 95 5 
2 47 53 85 15 
3* 62 22 56 32 
4 41 59 92 8 
5 64 36 67 33 
6 30 70 88 12 
7 31 69 84 16 
8* 35 42 85 3 
9 37 63 100 - 
10 15 85 90 10 
11 24 76 100 - 
12 73 27 90 10 
Frozen specimens were thawed at 4°C and extracted (10% w/v)  with a 
saline buffer (SB) containing several antiproteinases [15] to bring into 
solution the soluble or loosely-bound ChEs (SI), and later with 1% w/v  
Triton X-100 and antiproteinases in SB (STB) to detach the tightly-bound 
ChEs ($2). AChE and BuChE forms in the extracts S 1 and S 2 were 
resolved by centrifugation on sucrose gradients made with 0.5% Brij 96, 
and assigned to individual enzyme species according to previous sedi- 
mentation values [15,18]. Relative proportions of the separated ChE 
forms were calculated from the percentages of each form in the sedimen- 
tation profiles of S 1 and S 2 and from the amount of enzyme detached in 
each soluble fraction. The extracts of tumors with asterisk displayed low 
amounts of G4 A AChE and BuChE forms. 
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Fig. 2. Conversion of meningioma AChE dimers into monomers. A
mixture of S I +S 2 was subjected to sedimentation analysis and the 
enzyme peak dialyzed to remove sucrose. An aliquot was incubated with 
dithiothreitol and iodoacetate, and dialyzed. AChE forms in non-reduced 
(1) and reduced samples (2) were identified by sedimentation a alysis on 
sucrose gradients with Brij 96. The sedimentation marker was alkaline 
phosphatase (P). 
strated that the AChE dimers and monomers were intrinsic 
components of meningioma nd not derived from prote- 
olytic conversion of G 2 into G] forms, or vice-versa by 
oxidation of free cysteine residues in AChE subunits. 
Abundant 12.0S and small proportions of 5.4S and 4.0S 
BuChE forms were separated by sedimentation a alysis of 
the supernatants S 1 and S 2 in gradients with Brij 96 (Fig. 
1). The above enzyme forms probably corresponded to 
G4 H, G2 n and G H. Sedimentation analyses of S] or S 2 in 
gradients with Triton X-100 showed a single 12.0S BuChE 
form (profiles not shown), but the lighter components were 
undetected because the inhibitory effect of the salt-Triton 
X-100 mixture on BuChE activity [15]. The above results 
indicated that meningioma contained abundant hydrophilic 
G4 n and very low amounts of hydrophilic G2 H and G~ 
components. 
A comparison of the sedimentation profiles of ChE 
forms in normal and meningioma CSF revealed increased 
light AChE forms in the latter and the absence of signifi- 
cant differences in the BuChE patterns (Fig. 3). These data 
suggested that a fraction of the tumor amphiphilic G A and 
G A AChE was secreted to the CSF. 
3.3. Amphiphilic properties of cholinesterases in menin- 
gioma 
The amphiphilic or hydrophilic properties of the AChE 
and BuChE components were assessed by Triton X-114 
phase-partitioning and hydrophobic chomatography on 
phenyl-Agarose. About 70-80% of the AChE in a mixture 
of S 1 + S 2 was measured in the Triton X-114-rich phase 
and the rest in the aqueous phase. Opposite results were 
obtained when assaying BuChE, since 80% of the activity 
was recovered in the detergent-poor phase. Sedimentation 
analysis of the detergent-rich and detergent-poor phases 
(profiles not shown) confirmed the amphiphilic behaviour 
of the AChE forms and the hydrophilic properties of the 
BuChE species in meningioma. 
Application of hydrophobic homatography to the su- 
pernatant S~ obtained by extracting the tumor with SB 
revealed that 70-80% of the AChE was absorbed whereas 
AChE BuChE 
C P 1 C P 1 
° ' i  , i I ,  I ,  = ,  rO  
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Fig. 3. Typical sedimentation patterns of AChE and BuChE components 
in CSF from normal subjects (1) and from patients affected of menin- 
gioma (2). Lumbar CSF were analyzed on sucrose gradients made with 
Brij 96. Internal markers as in Fig. 1. 
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Fig. 4. Separation of hydrophilic and amphiphilic cholinesterases in 
meningioma by hydrophobic chromatography on phenyl-Agarose. 5 ml of 
the supernatant S~ were applied onto a 10 ml-colunm filled with the 
matrix. The hydrophilic proteins eluted with the equilibrium buffer (SB) 
and the amphiphilic molecules with Triton X-100 (2% w/v)  in SB 
(arrow). AChE (O)  and BuChE (©) were assayed in the collected 
fractions, and those with high activity pooled and subjected to sedimenta- 
tion analysis. 
90% of the BuChE activity passed freely through the 
matrix (Fig. 4). Amphiphilic 4.3S and 2.7S AChE species 
were identified in the bound fraction, and hydrophilic 
12.0S BuChE forms in the unretained fraction (Fig. 5). 
3.4. Treatment of brain AChE monomers with PIPLC 
We have previously reported [20] that a significant 
fraction of the AChE monomers and dimers in menin- 
Table 2 
Thermal inactivation constants of AChE monomers in meningioma nd 
brain 
AChE form Fast phase 
% rate k (min- ' ) tl/2 (min) 
HM-G~ 94.5 -I- 3.6 0.115 + 0.011 6.5 
HM-G~ 84.9+2.1 0.120+0.007 7.8 
HB-G~ 91.8+ 1.5 0.148+0.005 5.5 
RM-GI A 94.2+0.3 0.172+0.002 4.4 
A tumor rich in AChE monomers was extracted with SB containing 0.5% 
Triton X-100, and a fraction of the extract exposed to P1PLC to convert 
the amphiphitic AChE forms into their hydrophilic derivatives. The 
absence of enzyme dimers in the preparation was assessed by sedimenta- 
tion analysis, and the cleavage of the GPI anchor by phenyl-Agarose 
chromatography. Samples of human meningioma amphiphilic (HM-G A) 
and PIPLC-converted hydrophilic monomers (HM-G~) were heated at 
50°C for various periods of time, up to 40 min. The human brain 
GPI-devoid AChE monomers (HB-G A ) were isolated by phenyl-Agarose 
chromatography as described in Section 2.2, and heated as above. The 
inactivation curves were analyzed by a computer-assisted non-linear 
regression algorithm. The inactivation constant for rabbit skeletal muscle 
A AChE monomers (RM-G 1 ), GPI-devoid enzyme components [17], is also 
given for comparison. 
gioma possessed a glycosylphosphatidylinositol anchor. 
We tested now whether PIPLC was capable of converting 
brain amphiphilic monomers into hydrophilic molecules. 
This would help to establish a possible common origin of 
the light enzyme forms in the two tissues. 
The phospholipase C failed to convert he amphiphilic 
brain AChE monomers into their hydrophilic derivatives 
whether the treatment was carried out before or after 
incubation with alkaline hydroxylamine (sedimentation 
profiles not shown). Under identical conditions, the PI- 
PLC-resistant AChE dimers from human erythrocyte, 
which are known to lose the hydrophobic anchor by 
sequential treatments with alkaline hydroxylamine and PI- 
PLC [22], were fully converted into hydrophilic molecules. 
The above data indicated that, according to the classifica- 
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tion proposed by Massouli6 [1], the AChE dimers and 
monomers in meningioma re Type I forms because their 
amphiphilic haracter is provided by the attachment of a 
GPI anchor, whereas the monomers in brain are Type II 
species, the amphiphilic behaviour probably being caused 
by an exposed hydrophobic C-terminal polypeptide. 
3.5. Thermal inactivation of AChE monomers 
Separated AChE species from meningioma (G A and 
PIPLC-converted GH) and brain (G1 A) were assayed for 
their thermal stability. All the enzyme forms were unstable 
since 75-95% of the activity was lost when heated at 
50°C, for 40 min. No major differences in the rate constant 
for thermal inactivation of the enzyme forms were found 
(Table 2). This suggests that the conformation of the 
AChE subunits in Type I (meningioma) nd Type II (brain 
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Fig. 6. Binding of cholinesterases to lectins. Mixed S x + S 2 extracts from 
meningioma (M), human brain (B), aliquots of Triton X-100-solubilized 
AChE from erythrocyte (E) and diluted samples of plasma (P) were 
mixed with Sepharose 4B (control), Con A- (open bars), LCA- (striped 
bars), WGA- (grey bars) and RCA-Agarose (cross-hatched bars). After 
overnight incubation the lectin beads with bound proteins were sedi- 
mented by centrifugation, and the remaining AChE and BuChE activities 
assayed in the supernatant. The ChE activities measured in control 
supernatants were taken as the total enzyme and the percentage of lectin 
binding was calculated from the difference between the activities in 
control and lectin assays. The values show the results from at least 5 
separate xperiments. 
or muscle) monomers i very similar and that the cleavage 
of the GPI anchor in Type I monomers has little effect on 
the thermal stability of the AChE subunit. 
3.6. Interaction of AChE from meningioma, brain and 
erythrocyte with lectins 
Incubation of the supematants S 1 and S 2 from menin- 
gioma with several immobilized lectins revealed that AChE 
reacted to a notable extent with Con A, LCA and WGA. 
The AChE in both supematants was poorly recognized by 
RCA. Similar proportions of BuChE in S l and S 2 were 
associated to Con A, LCA, WGA and RCA. The results 
conceming the association of AChE and BuChE in a 
mixture of S~ + S 2 with the lectins are shown in Fig. 6. 
The low specific binding of AChE to RCA suggested that 
most of the enzyme was devoid of terminal galactose, the 
sugar involved in the reaction with RCA [27]. AChE in 
human brain and meningioma displayed similar patterns of 
interaction with lectins, but BuChE in the two sources 
differed in glycosylation since most of the enzyme in the 
neoplasm reacted with RCA, while the brain BuChE failed 
to do so (Fig. 6). Since BuChE in human plasma fully 
binds to RCA (Fig. 6), it remains to be clarified whether 
the meningioma enzyme is produced in the tumor cells or 
comes to some extent from plasma. 
The interaction of human erythrocyte AChE with lectins 
was also tested to evaluate a possible contamination of the 
enzyme in meningioma with globular dimers released from 
blood cells. A notable proportion of erythrocyte AChE 
reacted with LCA, WGA and RCA and to a lesser extent 
with Con A (Fig. 6). The strong interaction of meningioma 
AChE with Con A and the lack of association with RCA 
allowed us to rule out the erythrocyte origin of AChE in 
meningioma. 
4. Discussion 
Cholinesterase activity has been measured in brain 
[12,20,28] and non-brain tumors [3,13,29,30]. Moreover, 
three alternative AChE mRNAs have been identified in 
heterologous tumor cell lines and primary tumors [13], and 
a tumor-specific BuChE cDNA in glioblastoma nd neu- 
roblastoma [31]. The expression of ChEs in brain tumors 
and the possible appearance of aberrant enzyme forms in 
the CSF of patients might be useful for diagnostic pur- 
poses. In addition, changes in the tumor ChE activity or in 
the profile of molecular forms may be related with relapse 
or progress of the disease and therefore be considered as a 
prognostic measure or as a follow-up marker for particular 
tumors. Before this, a systematic study on the biochemical 
properties of ChEs in brain tumors must be made. This 
paper attempts to establish the structural features of 
cholinesterases in meningiomas, with emphasis in AChE in 
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order to distinguish it from the isoforms in brain and 
erythrocytes. The properties of ChEs in other brain tumors 
are under current research. 
Meningiomas derive from meningothelial racnoid cells, 
fibroblastic ells of mesenchimal origin, in an undifferenti- 
ated state since they express embryonic protein markers 
such as epidermal [32] and fibroblast [33] growth factor 
receptors. The epidermal and subepidermal mesenchymal 
cells of the prenatal rat lower limb show intense AChE 
immunoreaction [34]. It is therefore possible that fibroblas- 
tic meningeal cells in the developing brain express high 
ChE activity. The occurrence of cholinesterases in several 
fibroblast cell lines [35], as well as in meningioma might 
be related to their proposed morphogenic actions (see 
below). 
Despite the differences in the absolute values of AChE 
and BuChE activities in meningiomas [20], the relative 
percentages of enzyme solubilization i  the absence and in 
the presence of detergent remained fairly constant. The 
results on ChEs detachment indicated that AChE was 
firmly attached to meningioma cell membranes whereas 
BuChE was soluble or loosely-bound to membranes. The 
soluble extracts showed a rather simple composition of 
ChE forms: variable proportions of amphiphilic AChE 
dimers (G A) and monomers (GA), and abundant hy- 
drophilic BuChE tetramers (G4 H) along with small amounts 
of dimers (G2 H) and monomers (G~). 
Major G A and minor G~ and G A ACHE, and abundant 
G4 H, G A and low amounts of G~ BuChE forms have been 
reported to exist in human brain [15,36-38]. Moreover, 
G A, G A and G ¢ ACHE, and G4 H, G4 A and G~ BuChE 
forms have been identified in glioma [28], and G A, G A 
and G A AChE and G4 H BuChE species in neurinoma 
(Vidal et al., in preparation). 
The transcription of a single AChE gene suffices for the 
variety of molecular forms found in Torpedo, mouse and 
human tissues [2,3]. The human AChE gene contains 6 
exons and 4 introns and the BuChE gene 4 exons, the first 
of which is non-translatable and the second of which 
contains 83% of the coding sequence [2,3]. Several AChE 
transcripts arise through alternative splicing, but only one 
BuChE mRNA transcript has been identified to date in 
normal tissues [2,3]. Both assembly of the various gene 
exons to the distinct AChE mRNAs and oligomerization f
ChE subunits for building up the various molecular forms 
are tissue-specific. This explains why distinct cells show 
different patterns of AChE and BuChE forms. Since the 
profiles of ChE forms in the aforementioned brain tumors 
depend on the cells from which they arise, the specific 
sedimentation patterns may be exploited for diagnostic 
purposes. 
A fraction of meningioma G A and G A AChE forms are 
PIPLC-sensitive (Type I) and consequently should bear a 
GPI derivative [20], although the occurrence of 
glycolipid-devoid amphiphilic enzyme forms (Type II) 
cannot be ruled out. Since G 1 AChE in brain is fully 
resistant o PIPLC, it is unlikely that the meningioma 
enzyme arises from a contamination with neural tissue. 
Mammalian erythrocyte contains GPI-linked dimers of 
AChE [1]. The strong interaction of human erythrocyte 
AChE with RCA (80-90%) compared with the enzyme in 
meningioma (5-10%) means that it is unlikely that the 
tumor AChE originates from contamination with red blood 
cells. Consequently, the AChE dimers and monomers 
should be intrinsic enzyme forms expressed by the tumor 
cells. 
The increase of light AChE forms in the CSF of 
patients with meningioma suggests that the tumor cells 
may synthetize and secrete these forms to the external 
milieu. The distinct migration of CSF light AChE forms in 
Brij 96- and Triton X-100-containing sucrose gradients 
suggests that they display amphiphilic properties but fur- 
ther experiments are required to confirm this. 
As regards the origin of AChE forms in meningioma, it 
is worth mentioning that three alternative spliced mRNAs 
have been identified in heterologous tumor cells, primary 
tumors and normal fetal and adult tissues [13]. The three 
AChE mRNAs include the main species expressed in brain 
and muscle (built up with exons EI-E2-E3-E4-E6) and two 
additional transcripts with inserted regions downstream 
from the exon 4 domain. Assuming that the two latter 
transcripts are translated in tumors, the gene products 
would show the properties of precursors of GPI-linked 
proteins [13]. Since meningioma contains PIPLC-sensitive 
AChE forms, it is tempting to speculate that they arise 
from the efficient ranslation of enzyme subunits encoded 
by one of the above transcripts. The absence of G 4 AChE 
forms in meningioma might indicate that the mesenchymal 
cells from which they derive synthetize nzyme subunits 
which fail to self-associate o produce tetrameric assem- 
blies or, altenatively the cells are devoid of the assembly 
factors required for AChE tetramerization, but not for 
bui ld ing G 4 BuChE. An analysis of levels and composition 
of AChE mRNAs in meningioma nd glioma now in 
progress will clarify the molecular mechanisms underlying 
the expression of the enzyme in tumor cells. 
As regards the BuChE activity, abundant G4 H and minor 
G~ and G~ species were identified in meningioma. Hu- 
man plasma and lumbar CSF are rich in G4 H BuChE [25], 
and additional G~ forms occur in brain [15]. Most of 
BuChE in meningioma nd all the enzyme in plasma was 
absorbed to the lectins Con A, LCA, WGA and RCA- 
Agarose. Whether the enzyme is produced in the tumor 
itself or originates from plasma infiltration remains to be 
clarified. 
Several studies suggest hat ChEs are involved in cell 
proliferation and differentiation. The fate of hematopoietic 
stem cells is modified by the addition of AChE antisense 
oligonucleotides [39], and the irreversible inhibition of 
AChE by organophosphate may explain in the uncon- 
trolled proliferation of stem cells in leukemia [3]. A devel- 
opmental role has also been suggested for ChEs in devel- 
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oping chick motor axons [6,40] and rat dorsal root gan- 
glion neurons [41]. Glioma cells and Xenopus laevis em- 
bryos transfected with DNA constructs expressing human 
AChE underwent important morphological changes: rapid 
process extension in the former case [42] and ultrastruc- 
tural alterations in developing neuromuscular junctions in 
the latter [4]. 
As regards the possible involvement of ChEs in tumoro- 
genesis, it has been reported that AChE and/or BuChE 
genes are amplified in hemopoietic [3,14] and ovarian 
tumors [3,43], and this suggests that ChEs may participate 
in tumor formation by a yet unexplained mechanism. 
Nevertheless, the fact that megakaryocytopoiesis may be 
controlled with antisense oligonucleotides for BuChE [44] 
points to new alternatives for developing therapeutic treat- 
ments which may efficiently block the growth-related ef- 
fects of cholinesterases. 
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